Etrinabdione [CAS 1818428-24-8]

Etrinabdione (EHP-101; VCE-004.8) is an orally active, specific PPARγ and CB2 receptor dual agonist. Etrinabdione inhibits prolyl-hydroxylases (PHDs) and activates the HIF pathway. Etrinabdione, a semi-synthetic multitarget cannabinoquinoid, has potent anti-inflammatory activity. Etrinabdione attenuates adipogenesis and prevents diet-induced obesity[1][2].

[1818428-24-8]

C28H35NO3

433.58

O=C1C(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(C(NCC3=CC=CC=C3)=C1CCCCC)=O

Cannabinoid Receptor; HIF/HIF Prolyl-Hydroxylase; PPAR

CB2; PPARγ

99.16

DMSO : 50 mg/mL (ultrasonic)

-20°C, 3 years; 4°C, 2 years (Powder)

Room Temperature